Company Active LTD

Company profile

Nanna Therapeutics Limited

UK company 08328823, incorporated on 12 December 2012.

Nanna Therapeutics

Nanna Therapeutics Limited is a UK company with status Active founded in 2012 based in East of England.

Company number
08328823
Incorporated
12 Dec 2012
Companies House status
Active

Company identity

Founded / incorporated
12 December 2012

Company number 08328823

Verify at Companies House
Legal name
ASTELLAS ENGINEERED SMALL MOLECULES U.K. LIMITED
Company type
Private Limited Company
Region
East of England
Registered address
MERRIFIELD CENTRE
ROSEMARY LANE
CAMBRIDGE
CB1 3LQ
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Nanna Therapeutics Limited
CRN 08328823
2
Direct and ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Dec
2026

Accounts due

Accounts Due

Next accounts due date

19 Nov
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

05 Nov
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Mar
2025

Accounts filed

Accounts

Last accounts made up date

12 Dec
2012

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2017
Funded years
2017, 2019
Age at first award
4 years

Projects

2019 Feasibility Studies Lead participant

Transforming Drug Discovery by Nanoscale Chemistry and Screening Enabled by Machine Learning

1 Feb 2019 to 31 Jan 2020

Awarded
£580,924
Total cost £829,892

Nanna Therapeutics has invented a ground-breaking set of technologies which has the potential to change the way in which medicines are discovered, in terms of efficacy, safety, speed and cost. This could provide the UK economy a major boost by providing vastly expanded discovery capabilities and increased productivity to the wider pharmaceutical industry....

2017 Collaborative R&D Lead participant

Discovering Novel Antibiotics Agianst Highly Resistent Gram Negative Pathogens

1 Jan 2017 to 31 Mar 2019

Awarded
£917,760
Total cost £1,311,085

Nearly all of us have taken antibiotics: they really are a 'wonder drug' saving millions of lives every year, by specifically killing bacteria. They are rapidly becoming less effective as bacteria develop ways to resist them. An example of this is the spread of MRSA in hospitals. A recent review (The O'Neill Report) conducted by the UK government with the...

Product types

Collaborative R&D Feasibility Studies